Lifeward LFWD 深 滬
等待開盤 09-23 09:30:00 美东时间
6.94
-0.060
-0.86%
華盛通- 最 高7.18
- 今 開6.90
- 成交量 2046股
- 最 低 6.90
- 昨 收 7.00
- 總市值 1965.42万
- 52周最高 10.20
- 市盈率 靜 --
- 換手率 0.07%
- 52周最低 4.20
- 委 比 -73.90%
- 總股本 283.20万
- 歷史最高 91782.60
- 量 比 0.39
- 振 幅 4.00%
- 歷史最低 4.20
- 每 手 1
- 風險率 0.84%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Lifeward Sets Timeline for 2026 Shareholder Meeting
An update from Lifeward ( ($LFWD) ) is now available. Lifeward Ltd. has schedul...
09-16 05:50
Lifeward Announces Publication Of Researcher-Led Peer-Reviewed Study Showing Potential For Individuals With Chronic Spinal Cord Injury To Use Personal Exoskeleton To Perform Everyday Activities
Landmark independent study reports significantly improved task performance and satisfaction and lower pain compared with wheelchair use ReWalk users with chronic spinal cord injury were able to perform everyday kitchen and grooming activities while standing with a personal exoskeleton Publication a...
09-15 20:05
Lifeward announces CEO and CFO changes
Lifeward (LFWD) appointed Josh Hexter as interim chief executive officer effective September 1, 2026, succeeding Mark Grant. Rami Aviram will become chief financial officer effective November 1, 2026,...
09-01 04:19
Lifeward Appoints Josh Hexter As Interim CEO, Succeeding Mark Grant, Effective September 1; Names Rami Aviram CFO Effective November 1
Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the appointment of Josh Hexter as Interim Chief Executive Officer effective September 1, 2...
09-01 04:17
Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee
Nano Dimension Ltd. has appointed Nadav Kidron to its Board of Directors. Kidron, who is the CEO of Oramed Pharmaceuticals, will chair a new Strategy and Capital Allocation Committee aimed at maximizing shareholder value through evaluating capital allocation, potential returns, and strategic opportunities. With significant experience in public-company leadership and strategic repositioning, Kidron brings valuable insights to Nano Dimension’s next...
08-17 12:00
Lifeward Q2 Adj. EPS $(1.46) Misses $(1.34) Estimate, Sales $6.623M Beat $6.530M Estimate
Lifeward (NASDAQ:LFWD) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate of $(1.34) by 8.96 percent. This is a 61.07 percent increase over losses of $(3.75) per share from the same period last year. The company reported quarterly sales of $6.623 million which...
08-14 21:18
Lifeward Launches Pilot Program with Ottobock Care to Expand National Access to ReWalk® Personal Exoskeleton
Lifeward, a biomedical innovation company, has launched a six-month pilot program with Ottobock Care to expand access to the ReWalk 7 Personal Exoskeleton. Ottobock Care, a leading U.S. mobility technology patient care organization, brings clinical expertise and infrastructure to support patient access and training. The partnership aims to increase awareness of ReWalk 7 among rehabilitation hospitals and spinal cord injury centers, while building...
08-05 12:00
Nano Dimension Announces Appointment of Interim Chief Executive Officer and Chairman of the Board
Nano Dimension Ltd. has appointed Moshe Rozenbaum as Interim CEO and Phillip Borenstein as Chairman of the Board. Rozenbaum will support business continuity while the Board evaluates strategic priorities. Borenstein expressed confidence in Rozenbaum's leadership, emphasizing focus on long-term shareholder value. Rozenbaum brings extensive corporate development and financial expertise. Nano Dimension provides advanced digital manufacturing technol...
07-21 20:05
Lifeward Secures Growth Capital to Accelerate Commercial Expansion with Up to $11.2 Million in Strategic Financing
Lifeward Ltd. (Nasdaq: LFWD) has secured an initial $5.6 million in senior secured convertible notes and warrants, with an additional $5.6 million available upon achieving specific commercial milestones, including a 150% increase in ReWalk® unit sales or its shares trading at $13.80 for ten consecutive days. This financing aims to accelerate the commercialization of its restorative healthcare platform, expand its reimbursement-backed distribution...
07-07 20:15
电话会总结 ｜ Lifeward(LFWD)2025财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Lifeward业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** 2025年全年总营收2200万美元，较2024年的2570万美元下降14%。各产品线表现分化：ReWalk个人外骨骼营收850万美元，与上年890万美元基本持平；MyoCycle FES自行车营收60万美元，同比下降50%；AlterG产品营收1290万美元，同比下降18%。 **盈利能力：** GAAP毛利润840万美元，毛利率38.2%，较2024年的820万美元和32%毛利率有所改善。Non-GAAP毛利润900万美元，毛利率41%，低于2024
05-22 12:17
